These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32323582)

  • 1. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
    McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
    J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv.
    MacDonald K; McBride A; Alrawashdh N; Abraham I
    J Med Econ; 2020 Dec; 23(12):1466-1476. PubMed ID: 33023360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
    MacDonald K; Alrawashdh N; McBride A; Abraham I
    Future Oncol; 2021 Nov; 17(33):4561-4570. PubMed ID: 34382416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.
    McBride A; MacDonald K; Abraham I
    Leuk Res; 2021 Jul; 106():106591. PubMed ID: 33957339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
    McBride A; Alrawashdh N; MacDonald K; Abraham I
    Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment.
    McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
    J Med Econ; 2021; 24(1):598-606. PubMed ID: 33866947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
    Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
    J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
    Trautman H; Szabo E; James E; Tang B
    J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
    McBride A; Balu S; Campbell K; Bikkina M; MacDonald K; Abraham I
    Future Oncol; 2017 Oct; 13(25):2285-2295. PubMed ID: 28870106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
    Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
    J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
    Grewal S; Ramsey S; Balu S; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
    Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
    Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.
    MacDonald K; Pondel M; Abraham I
    J Med Econ; 2024; 27(sup3):24-33. PubMed ID: 39016841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    MacDonald K; Pondel M; Abraham I
    J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
    Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
    Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.